Skip to main content
Clinical Trials/NCT01353235
NCT01353235
Completed
Phase 3

A Prospective Randomized Trial of Systemic Corticosteroids (Oral Prednisolone) in Severe Exacerbation of COPD Requiring Ventilatory Assistance

Fekri Abroug1 site in 1 country317 target enrollmentApril 2010

Overview

Phase
Phase 3
Intervention
usual care
Conditions
COPD Exacerbation
Sponsor
Fekri Abroug
Enrollment
317
Locations
1
Primary Endpoint
ICU mortality rate
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

Evaluation of systematic administration of oral prednisolone (1mg/Kg/day) as an add on therapy in Chronic Obstructive Pulmonary Disease (COPD) patients admitted to intensive care unit (ICU) for severe exacerbation of COPD. Patients with pneumonia are excluded.

Randomization is stratified according to ventilatory support: non invasive or conventional ventilation.The major outcome is the ICU mortality rate in overall population and stratified according to ventilatory mode (noninvasive ventilation (NIV) versus conventional).

Secondary outcomes are superinfection necessitating a new antibiotic course, Length of mechanical ventilation (MV) (and ventilatory free days), Length of ICU stay, The frequency of gastric bleeding episodes that of frequency of hyperglycemic episodes.

Registry
clinicaltrials.gov
Start Date
April 2010
End Date
June 2013
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Fekri Abroug
Responsible Party
Sponsor Investigator
Principal Investigator

Fekri Abroug

ead of the ICU

Hôpital Universitaire Fattouma Bourguiba

Eligibility Criteria

Inclusion Criteria

  • All COPD patients (according to the ATS definition) experiencing acute exacerbation originating in acute respiratory failure and requiring ICU admission will be included in the study.
  • COPD exacerbation is defined by the increased frequency of cough, volume and purulence of sputum and that of wheeze.
  • Acute respiratory failure is defined by the presence of hypercapnia with PaCO2 \>45mmHg associated with pH \> 7.35 and signs of respiratory muscle fatigue (contraction of accessory respiratory muscles, thoracoabdominal swinging ,..).

Exclusion Criteria

  • Asthmatic patients defined by a reversible obstructive disease following nebulized bronchodilators,
  • Patients with uncontrolled left heart failure,
  • AECOPD patients with a radiologically documented pneumonia,
  • Systemic corticotherapy within 30 days before screening,
  • contra-indication to corticosteroids (active gastroduodenal ulcer, uncontrolled sepsis, etc. ..)

Arms & Interventions

usual care

Intervention: usual care

Prednisolone

1mg/kg/day prednisolone for the entire ICU stay and a maximum of 10 days

Intervention: Prednisolone

Outcomes

Primary Outcomes

ICU mortality rate

Time Frame: ICU stay (on average patients will be followed 30 days)

Secondary Outcomes

  • Length of MV (and ventilatory free days)(ICU stay (on average patients will be followed 30 days))

Study Sites (1)

Loading locations...

Similar Trials